We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App





Horiba Showcases Latest Hematology and Hemostasis Solutions at EUROMEDLAB 2022

By LabMedica International staff writers
Posted on 11 Apr 2022
Print article
Image: Horiba Medical at the EUROMEDLAB 2022 (Photo courtesy of Horiba Medical)
Image: Horiba Medical at the EUROMEDLAB 2022 (Photo courtesy of Horiba Medical)

Horiba Medical (Kyoto, Japan) showcased its hematology and hemostasis solutions at the EUROMEDLAB 2022 which took place from April 10 to 14 at the ICM Internationales Congress Center, Munich, Germany. The company also presented scientific posters on its high range hematology solutions during the poster session time.

At its exhibition booth, Horiba showcased its automation high-end HELO Global Hematology Solution covering all the needs of a high throughput automated hematology platform. Thanks to its data, tube management, waste, blood film and digitalization management capability, HELO not only addresses all the needs of laboratories, but helps to optimize their TAT, floor space and reagent storage. Among its Yumizen range of hematology solutions, Horiba displayed its Yumizen H2500/H1500 and the Yumizen H550 hematology analyzers. The Yumizen H2500/H1500 has a real throughput of 120 samples per hour for CBC-DIFF NRBC and slides and come with on board reagents (5 for Yumizen H2500 and 4 for Yumizen H1500). Along with testing for up to 55 parameters, their automatic 360°C rotative sample mixing provides perfect homogeneity. On the other hand, the Yumizen H550 is a compact 6-diff hematology analyzer with an auto sampling system which aims at providing a full walk away capability to a variety of clinical environments: hospitals, satellite labs, emergency care, small independent labs, and doctors’ offices.

Among its Yumizen range of hemostasis solutions, Horiba displayed its Yumizen G1550/G1500 and Yumizen G400 hemostasis analyzers. The Yumizen G1550/G1500 automated analyzer offers routine and specialized testing in a single analysis system along with liquid and ready-to-use reagents for 80% of laboratory activity. It offers up to eight measuring channels with two wavelength combinations, continuous loading, and simplified anteriority management thanks to a large database of 1,000,000 results. The Yumizen G400 semi-automated hemostasis analyzer offers four independent measuring channels and 20 incubation positions and is easy to operate with an innovative user interface. Other solutions on display at the Horiba EUROMEDLAB 2022 exhibition booth included the Yumizen SPS slide maker, the CellaVision DC-1 digital cell morphology system, the Yumizen P8000 middleware and expert validation station and the Yumizen T6000 automated conveyor.

Related Links:
Horiba Medical 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.